3
H index
0
i10 index
13
Citations
Office of Health Economics | 3 H index 0 i10 index 13 Citations RESEARCH PRODUCTION: 8 Articles 11 Papers RESEARCH ACTIVITY:
EXPERT IN:
MORE DETAILS IN: ABOUT THIS REPORT:
|
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Christopher James Sampson. | Is cited by: | Cites to: |
Journals with more than one article published | # docs |
---|---|
PharmacoEconomics - Open | 2 |
Working Papers Series with more than one paper published | # docs |
---|---|
Contract Research / Office of Health Economics | 4 |
MPRA Paper / University Library of Munich, Germany | 3 |
Grant-Funded Research / Office of Health Economics | 2 |
Briefing / Office of Health Economics | 2 |
Year ![]() | Title of citing document ![]() |
---|---|
2024 | Optimal intertemporal curative drug expenses: The case of hepatitis C in France. (2024). Magnac, Thierry ; Dubois, Pierre. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629624000067. Full description at Econpapers || Download paper |
2024 | ‘Managing values’ in health economics modelling: Philosophical and practical considerations. (2024). Winsberg, Eric B ; Harvard, Stephanie. In: Social Science & Medicine. RePEc:eee:socmed:v:358:y:2024:i:c:s027795362400710x. Full description at Econpapers || Download paper |
Year ![]() | Title ![]() | Type ![]() | Cited ![]() |
---|---|---|---|
2024 | Marginal cost per QALY estimates: What are they good for? In: Health Policy. [Full Text][Citation analysis] | article | 0 |
2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing. [Citation analysis] | paper | 3 |
2021 | How is Quality of Life Measured for Health Technology Assessments? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
In: . [Full Text][Citation analysis] | paper | 0 | |
In: . [Full Text][Citation analysis] | paper | 0 | |
In: . [Full Text][Citation analysis] | paper | 0 | |
In: . [Full Text][Citation analysis] | paper | 0 | |
In: . [Full Text][Citation analysis] | paper | 1 | |
In: . [Full Text][Citation analysis] | paper | 0 | |
2013 | Cost implications of treatment non-completion in a forensic personality disorder service In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
2013 | Happy and healthy: a joint model of health and life satisfaction In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
2013 | The relationship between individual risk and cost-effectiveness in screening interventions In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
2021 | Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. In: Medical Decision Making. [Full Text][Citation analysis] | article | 1 |
2022 | Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
2013 | Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776 In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 0 |
2019 | Transparency in Decision Modelling: What, Why, Who and How? In: PharmacoEconomics. [Full Text][Citation analysis] | article | 4 |
2017 | Model Registration: A Call to Action In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 4 |
2022 | NICE and the EQ-5D-5L: Ten Years Trouble In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
2024 | Is anchoring at ‘dead’ a theoretical requirement for health state valuation? In: Health Economics. [Full Text][Citation analysis] | article | 0 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated February, 4 2025. Contact: CitEc Team